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Abstract
Background: A vaccine that elicits durable, powerful anti-HIV immunity remains an elusive goal.
In these studies we tested whether multiple treatments with viral vector-delivered HIV envelope
antigen (gp120), with and without IL-15, could help to approach that goal. For this purpose, we used
recombinant Tag-deleted SV40-derived vectors (rSV40s), since they do not elicit neutralizing
antibody responses, and so can be given multiply without loss of transduction efficiency.
Methods: SV(gp120) carried the coding sequences for HIV-1NL4-3 Env, and SV(mIL-15) carried
the cDNA for mouse IL-15. Singly, and in combination, these two vectors were given monthly to
BALB/cJ mice. Cytotoxic immunity and cytotoxic memory were tested in direct cytotoxicity assays
using unselected effector cells. Antibody vs. gp120 was measured in a binding assay. In both cases,
targets were P815 cells that were stably transfected with gp120.
Results: Multiple injections of SV(gp120) elicited powerful anti-gp120 cytolytic activity (>70%
specific lysis) by unselected spleen cells. Cells from multiply-immunized mice that were rested 1
year after their last injections still showed >60% gp120-specific lysis. Anti-gp120 antibody was first
detected after 2 monthly injections of SV(gp120) and remained elevated thereafter. Adding SV(mIL-
15) to the immunization regimen dramatically accelerated the development of memory cytolytic
responses, with ≥ 50% specific lysis seen 1 month after two treatments. IL-15 did not alter the
development of antibody responses.
Conclusions: Thus, rSV40s encoding antigens and immunostimulatory cytokines may be useful
tools for priming and/or boosting immune responses against HIV.
Introduction
The development of an effective vaccine against HIV has
been hindered by a variety of problems. The high muta-
tion rate of the virus itself is such that it represents a mov-
ing antigenic target during the course of an infection [1-4].
Furthermore, HLA-A and -B expression is directly
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I MHC-export to the cell surface by HIV-1 Nef and Vpu),
so that efficient antigen presentation is compromised
[1,5].
Compared to administration of protein antigen or naked
DNA, an infectious vector could be more effective at
enhancing antibody and cytotoxic responses against a
transgene product. Application of such a strategy, how-
ever, has been often complicated by the development of
neutralizing immune responses, principally antibodies,
against vector coat antigens [6-10]. These neutralizing
antibodies arise because the viral vectors enter cells largely
through endocytic pathways. Their capsids, like most
other particulate antigens, are processed at the time of
infection and presented to the immune system. Resulting
immune responses neutralize subsequent injections of the
vector, and so limit the ability of that vector to be used
repeatedly to boost immune responses.
This limitation can be circumvented by repeatedly chang-
ing the serotype of the antigen-carrying vector, or by using
recombinant Tag-deleted SV40-derived gene delivery vec-
tors (rSV40s) for immunization. Several studies have
shown, both directly and indirectly, that rSV40 vectors do
not elicit detectable neutralizing antibodies [11-13]. Even
repeated administration of single [11,12] or different [13]
rSV40 vectors in normal, immunocompetent hosts does
not generate antibodies against the vector capsid proteins
sufficiently to impair the ability of these vectors to deliver
their genes efficiently in vivo.
The explanation for this unusual state of affairs may lie in
the fact that SV40 enters cells via caveolae and thence trav-
els directly to the nucleus, bypassing cellular antigen
processing [14-16]. Thus, only proteins expressed by virus
can elicit immune responses. Since, for Tag-deleted rSV40
vectors (unlike wild type SV40), capsid proteins are not
expressed, immune responses can only be generated by
transgene products [11,12]. Whether for this or for other
reasons, rSV40 vectors can be used multiple times to
prime and/or boost immune responses against antigens
encoded by the transgenes they carry [13,14]. We have
previously shown that powerful transgene-specific cyto-
lytic and serum antibody responses can be detected in
mice inoculated with rSV40 carrying the cDNA for
SIVmac239 envelope glycoprotein gp130 [12]. Four to
five monthly immunizations were adequate to produce
>50% specific lysis of envelope-expressing target cells,
even with effector:target ratios of 10:1 [12].
Other investigators have reported that co-administration
of vectors carrying immunostimulatory cytokines was use-
ful in augmenting anti-lentiviral immune responses [17-
19]. IL-15 has various immunostimulatory and immu-
nomodulatory effects, among which is the ability to
upregulate activated T cell proliferation and induce cyto-
toxic T cell activity [20]. It also promotes cytotoxic T cell
memory [21,22].
Both antibody and cell-mediated immune responses may
be useful to protect from HIV infection and progression to
AIDS [23-26]. However, there is a particularly good corre-
lation between long-term non-progression to AIDS and
strong CTL responses in HIV-positive individuals [22,27-
31]. Weak CTL responses are generally seen in those who
progress rapidly to disease, and in children. Because of the
importance of a virus-specific cytotoxic T cell (CTL)
response, one of the major aims of any vaccine should be
to elicit strong HIV-specific CTL responses [32,33].
We used rSV40s to study the generation and longevity of
both humoral and cell-mediated responses in an effort to
generate immune responses against the HIV-1 envelope
glycoprotein, gp120. We also tested whether co-immuni-
zation regimens involving rSV40 delivery of both IL-15
and gp120 augmented and/or accelerated SV40-mediated
immune responses further.
Methods
Cell Lines
The murine mastocytoma cell line P815 (ATCC, Bethesda,
MD, USA) was used, and maintained in culture with Dul-
becco's Modified Eagle's medium (DMEM), supple-
mented with 10% newborn calf serum (NCS) (Gibco
BRL/Life Technologies, Grand Island, NY, USA). COS-7
cells (ATCC, Bethesda, MD, USA), were used to expand
stocks of recombinant SV(gp120) and SV(mIL-15)
viruses. Cytotoxic lymphocytes were obtained from
spleens of immunized mice, and cultured in RPMI-1640
(Gibco BRL/Life Technologies, Grand Island, NY, USA)
supplemented with 10% NCS (RPMI-10). Rabbit kidney
fibroblasts (RK13 cells) and CV-1 cells (African green
monkey kidney cells) were obtained from ATCC
(Bethesda, MD, USA). RK13 cells were used to propagate
stocks of VCB41, a vaccinia virus vector carrying HIV-
1NL4-3 envelope gp120 sequence.
Mice
BALB/cJ mice aged 6–8 weeks were purchased from Jack-
son Laboratories, Bar Harbor, ME, USA. They were fed and
housed in accordance with American Association for
Accreditation of Laboratory Animal Care standards. Use
of mice in the laboratory protocols described was
approved by the Thomas Jefferson University Institutional
Animal Care and Use Committee.
Generation of SV(gp120)
A 1.6 kb DNA fragment encoding gp120 from HIV-1NL4-
3 was made by PCR using primers with engineeredPage 2 of 11
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(a plasmid containing an SV40 genome, in which large T
antigen gene was replaced by cytomegalovirus (CMV)
immediate early promoter and downstream polylinker),
giving pT7A5-gp120. To make SV(gp120), the SV(gp120)
genome was released from the carrier plasmid by restric-
tion digestion, and used to make recombinant virus in
COS-7 cells as described previously [34]. Virus stocks were
purified and titered, as described elsewhere [34].
SV(HBS), a control virus for these studies, carries hepatitis
B surface antigen (HBsAg), and has been reported previ-
ously [11].
Generation of SV(mIL-15)
To generate a recombinant SV40 virus with the murine IL-
15 transgene (SV(mIL-15)), mIL-15 cDNA was cloned
into pSL-4p, which contains a Tag-deleted SV40 genome
[[35], Vera, et al., in preparation], to yield prSVmIL-15.
Virus was made from this plasmid in COS-7 cells as previ-
ously reported [32].
Immunization of mice
Mice were given monthly 1 × 109 infectious units (IU) of
SV(gp120) ± SV(mIL-15) intraperitoneally (IP). In some
studies, final administrations included both IP and subcu-
taneous (SQ) inoculations. SV(HBS) was used as a control
antigen-carrying vector. Specific immunization schedules
are described in the Results section, below.
Stably-transfected P815 target cells for cytotoxicity assays
Production of HIV Env-expressing stably transfected tar-
gets is similar to the procedure used for generating SIV
Env-expressing targets [12]. Briefly, gp120 cDNA was
cloned into pCDNA3. The resulting plasmid, pcgp120,
was co-transfected into P815 cells together with the neo-
mycin resistance-carrying plasmid, pSV2Neo. Transfected
cells were selected in G418-supplemented DMEM-10,
then cloned by limiting-dilution. Viable clones were
expanded, assayed for gp120 expression by flow cytome-
try, and maintained thereafter in G418-supplemented
medium.
Flow cytometric detection of cell surface gp120 expression
Flow cytometry was used to verify gp120 expression on
the surface of P815 cells. A recombinant vaccinia virus car-
rying HIV-1NL4-3 gp120 (VCB41, NIH AIDS Reference
Reagent Repository Program (NIH-ARRRP)) was used
both as a positive control for gp120 expression and also to
generate gp120-expressing target cells in some experi-
ments. Cells that had been stably-transfected with plas-
mid gp120, or infected with VCB41 both expressed
gp120, as assayed by flow cytometry (Coulter-Epic, Kim-
mel Cancer Center, TJU) (data not shown).
The gp120-expressing P815 population was then cloned
by limiting dilution. Clonal outgrowths were then reana-
lyzed by cytofluorimetry (FACS, data not shown) and the
single clone expressing the highest levels of gp120, clone
24, was used in subsequent studies as a target for cytotox-
icity assays.
Anti-gp120 binding-antibody detection using a CELISA
An ELISA method was used to assay the activity of anti-
gp120 antibodies elicited by immunization of the mice
with SV(gp120) ± SV(mIL-15). The strategy for our
appraoch to testing for antibodies vs. HIV Env is similar to
one we have used to measure binding activity vs. SIV Env
[12]. Briefly, a cell-based assay was developed using
VCB41-infected P815 cells (cells were infected with virus
for 48 hours prior to being used in assay) as control tar-
gets. Sera were taken from mice at 2- and 4-week intervals
after immunization(s). Antibody reactivity vs. cell mem-
brane-expressed gp120 was tested by measuring A405nm of
test sera vs. VCB41-infected P815 cells, subtracting A405nm
due to binding to wild type (wt) VV-infected P815 cells,
and also subtracting A405nm of control sera from mice
immunized in parallel with a control rSV40, SV(HBS)
Measurement of cytotoxic lymphocyte activity by specific 
lysis of 51Cr-labeled target cells
Wild type (wt) P815 cells, or clone 24 P815 cells express-
ing gp120 were the target cells for unselected lymphocytes
from spleens of mice immunized with SV(gp120) (±
SV(mIL-15)), or SV(HBS) as control. Where SV(gp120)
was used alone, P815 cells infected with wt vaccinia virus
or VCB41 were target cells for spleen cells of immunized
mice.
Mice were boosted simultaneously with 1 × 109 IU intra-
peritoneally (IP) and 1 × 108 IU subcutaneously (hind
footpads) usually 4 d before assay, but up to 1 month
prior to assay, to test cytolytic lymphocyte memory.
Spleen cell concentrations adjusted to 2 × 106 / ml with
RPMI-10.
In some assays of cytotoxic lymphocyte memory, effector
cells were harvested 1 month after the final injection.
Effector cells from immunized mice were prepared as
described, but in addition, were incubated with 5 µg/ml
Concanavalin A (Con A, Sigma Chemical Co., St. Louis,
MO) overnight, prior to assay. Con A-stimulated cells
were then harvested, washed once in RPMI-10, and then
used with target cells in the assay.
P815 target cells were washed, then labeled with 51Cr
(ICN Biomedicals, Inc., Irvine, CA, USA) (100 µCi per 1 ×
106 cells) at 37°C, 5% CO2 for 4 h as described previously
[12]. Afterwards, target cells were washed, then plated in
triplicate with effector cells (splenocytes) at effector:targetPage 3 of 11
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CO2 for 4 hours. Supernatant 51Cr was counted (1282
Compugamma CS, LKB) [12]. Mean specific lysis was cal-
culated as:
Mean c.p.m. for gp120-immunized effector cells mixed
with gp120-expressing targets, minus the mean c.p.m.
control (SV(HBS))-immunized effector cells vs gp120-
expressing targets, and expressed as a percentage of the
maximal target cell lysis (target cells incubated with 1%
Triton-X). Background release of 51Cr from wild type tar-
get cells was subtracted. Thus:
% specific 51Cr release = {[c.p.m. 51Cr released by
SV(gp120)-immune populations from gp120-expressing
P815 cells] minus [c.p.m. 51Cr released by SV(HBS)-
immune lymphocytes from gp120-expressing P815
cells]}, divided by [c.p.m. 51Cr released by Triton X-100
from gp120-expressing P815 cells]. The same calculations
were done for lysis of wild type P815 cells by gp120-
immune and control-immune effector populations. These
numbers were then subtracted from the calculated 51Cr
release above to determine the gp120-specific lysis of tar-
get cells by SV(gp120)-immunized effector cells.
Western analysis of IL-15 expression in SV(mIL-15)-
transduced P815 cells
P815 cells were transduced with SV(mIL-15) ×1 at m.o.i.
= 100. Culture supernatants were harvested at several
times post-transduction, and stored at -80°C. At day 6
post-transduction, a well of cells was harvested and lysed
(2% NP40, 50 mM Tris pH7.4,150 mM NaCl, 1 mM
EDTA, 10% Glycerol + protease inhibitor cocktail (25×
stock Complete™ EDTA-free protease inhibitor cocktail,
Roche Diagnostics GmbH, Mannhein, Germany)).
Remaining wells were activated non-specifically with 5
mg/ml Con A, and supernatants harvested at various
times thereafter. 3 days after con A stimulation, cells were
lysed as described above. 50 µg of each culture superna-
tant or lysate were loaded on a 4–20% Tris-HCl gradient
gels (Ready Gel, Bio-Rad, Hercules, CA, USA). 50 ng
recombinant human IL-15 was used as a positive control.
Samples were electrophoresed, and blotted to PVDF
membranes (Immobilon™-P, Millipore Corporation, Bed-
ford, MA). Blots were blocked overnight at 4°C with 5%
milk in PBS + Tween-20 (0.05%). Rabbit anti-mouse IL-
15 (Abcam, Cambridge, UK) was used as primary anti-
body, (diluted 1:500 with PBS-Tween), for 2 h at 37°C.
Horseradish peroxidase (HRP)-conjugated goat anti-rab-
bit IgG (Jackson ImmunoResearch, West Grove, PA) was
used at 1:10,000 dilution in PBS-Tween, for 1 h at room
temperature. Signal was detected with chemilumines-
cence reagent (ECL Plus, Amersham Pharmacia Biotech
UK Ltd., Little Chalfont, UK,)
Assaying for IFNγ production stimulated by IL-15
COS-1 cells were infected with SV(mIL15) or SVLUC (car-
rying luciferase) as a negative control. 24 h later, the
media were changed and cells incubated 48 h in 500 µl of
RPMI 10% serum/well. Fresh mouse spleen cells (5000/
well) then cultured 48 h with 100 µl of cell supernatant +
100 µl of RPMI 10% serum. IFNγ ELISA (Pharmingen)
was performed on the supernatant from these cultures.
Results
Stably transfected HIV-1 gp120-expressing P815 cells
P815 cells stably transfected to express HIVNL4-3 gp120
were selected and cloned by limiting dilution (see Meth-
ods). We used flow cytometry to identify the clone most
strongly positive for cell membrane gp120. Compared to
other stably-transfected clones, "clone 24" expressed
gp120 at the cell membrane best (data not shown).
VCB41-infected and SV(gp120)-transduced P815 cells
also expressed substantial cell membrane gp120. Control
wtP815 cells, or P815 cells infected with wt VV did not
(data not shown).
Therefore, clone 24 cells were used to assay gp120-specific
immune responses. In both antibody and cytotoxicity
assays, two different types of background were subtracted
from the responses of gp120-immunized mice: serum
binding or cellular reactivity from gp120-immunized ani-
mals vs. wt P815 cells and reactivity from control (i.e.,
SV(HBS))-immunized rSV40-immunized mice vs. clone
24 cells. Thus, data presented below reflect gp120-specific
responses against clone 24.
Immunization with SV(gp120)
Normal BALB/c mice were inoculated with SV(gp120),
and their sera were assayed for reactivity vs. gp120 by
CELISA. The details of this cell-based ELISA, or CELISA, as
described in Methods. Specific binding antibody activity
was first statistically significant, compared to prebleed
sera 2 weeks after the second inoculation of SV(gp120) (P
= 0.000332, using two-tailed Student's t-test) and reached
a plateau after the third inoculation (P = 0.000000316 by
the same analysis) (Figure 1). Additional immunizations
beyond the third did not further increase detectable anti-
body levels (data not shown).
Cytolytic responses against gp120: testing for cytotoxic 
lymphocyte memory
An effective anti-lentiviral immunization regimen should
generate cytotoxic memory cells. To see if SV(gp120) treat-
ment could do this, mice were immunized once with
SV(gp120) IP, then sacrificed 1 month later, without fur-
ther treatment. In order to lyse target cells, committed
cytotoxic cells require activation. However, to avoid anti-
gen-specific selection and specific stimulation only of
gp120-reactive cytotoxic cells, splenic lymphocytes werePage 4 of 11
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Con A. A single immunization with SV(gp120) alone elic-
ited only weak memory lytic responses (≤ 10% specific
lysis) against gp120-expressing target cells (Figure 2).
A second group of animals received a second inoculation
with SV(gp120) one month after the first, then were
assayed the same way one month later for anti-gp120
cytolytic activity. These mice made stronger specific mem-
ory responses (15–20% specific lysis) than did animals
given only a single inoculation (P ≤ 0.04, by Student's t-
test, comparing 2 injections with just one) (Figure 2).
To test whether SV(gp120) could elicit very long term
cytotoxic lymphocyte memory, mice were immunized
monthly ×8 with SV(gp120) IP. A final IP inoculation
with SV(gp120) was given 1 year after their eighth immuni-
zation. They were sacrificed 4 days later, and direct gp120-
specific splenocyte cytotoxicity was measured. Unselected
spleen cells from all animals made very strong (≥ 50%
specific lysis) gp120-specific cytolytic responses (mean
specific lysis of 61% ± 4.2).
IL-15 expression and secretion in SV(mIL-15)-transduced 
P815 cells
Because higher levels of durable memory cytotoxic
responses could be achieved with repeated injections of
SV(gp120), and lower levels were seen with 2 injections,
we tried to accelerate development of such responses
using IL-15, delivered by transduction. To determine if IL-
15 could be expressed by transduction, P815 cells were
transduced with SV(mIL-15) at m.o.i. = 100. Culture
supernatants were harvested 36, 72 and 144 hours later, at
which point the cultured cells were activated with Con A.
Culture supernatants were collected at 24 and 72 hours
post-activation. Supernatants were assayed for IL-15 secre-
tion by Western analysis as described in Methods, using
rabbit antibody vs. murine IL-15 (Figure 3). The positive
Serum antibody against HIV-1NL4-3 envelope glycoprotein gp120 in mice receiving multiple inoculations of SV(gp120) BALB/cJ mice were immunized at monthly int r als with 1 × 109 infectious units (IU) SV(gp120), IPFig re 1
Serum antibody against HIV-1NL4-3 envelope glycoprotein gp120 in mice receiving multiple inoculations of SV(gp120) BALB/cJ 
mice were immunized at monthly intervals with 1 × 109 infectious units (IU) SV(gp120), IP. They were bled biweekly. Gp120-
specific antibody reactivity was assayed by CELISA, as described in Methods and in reference #12. Specific binding of HIV-1 
Env is shown here as specific A405nm, ± S.E.M.
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60% sequence homology with murine IL-15). IL-15
secretion was detectable, but just barely so, in unstimu-
lated culture supernatants. It was abundant by 72 hrs
post-stimulation. These data were used in planning co-
transduction experiments.
The functionality of the IL-15 produced in this fashion
was tested by exploiting the ability of IL-15 to elicit pro-
duction of IFN-γ by lymphocytes. Thus, CV-1 and COS-7
cells (African green monkey kidney cells) were transduced
by SV(mIL-15), then cultured for 72 hrs. Control cultures
of the same cells were transduced with SVLUC (carrying
luciferase as a transgene). Normal mouse spleen cells were
cultured for 42 hrs in 200 µl of the resulting culture super-
natants. Production of IFN-γ by the spleen cells was meas-
ured by ELISA. Supernatants from COS-7 and CV-1 cells
elicited respectively 2056 ± 363 pg/ml and 880 ± 196 pg/
ml IFN-γ. Supernatants from SVLUC-transduced cells did
not elicit detectable interferon secretion by spleen cells
(<20 pg/ml).
Effects of IL-15 in cytotoxic lymphocyte responses against 
gp120
To determine whether coordinate administration of
SV(mIL-15) plus SV(gp120) improved cytolytic responses
against gp120, mice were given two sets of injections IP,
one month apart. Normal BALB/c mice received IP with
109 IU of rSV40: one group was given SV(mIL-15) alone,
and one group SV(gp120) alone. Three other groups
received both SV(mIL-15) and SV(gp120): either SV(mIL-
15) followed 3 days later by SV(gp120), or SV(gp120)
first, followed by SV(mIL-15). The final group was given
both SV(mIL-15) and SV(gp120) simultaneously. The 3
day separation between the two vectors was used because
of the strength of the signal for secreted IL-15 by Western
Specific cytolytic activity against HIV-1NL4-3 gp120 in mice immunized with SV(gp120) and assayed one month after final inj tionFigure 2
Specific cytolytic activity against HIV-1NL4-3 gp120 in mice immunized with SV(gp120) and assayed one month after final injec-
tion. BALB/cJ mice were immunized twice with SV(gp120) IP at monthly intervals. Splenocytes were harvested one month after 
final inoculation. Unselected effector cells were added to 51Cr-labelled target cells and specific lysis of gp120-expressing cells 
was calculated as described in Methods, ± S.E.M. Results shown here represent ≥ 3 independent determinations per data set.
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month later, unselected spleen cells were assayed as
described above for cytolytic activity against gp120-
expressing clone 24 cells.
Adding IL-15 to the immunization regimen greatly
increased gp120-specific cytolytic responses (Figure 4).
Also, the timing of cytokine administration relative to
SV(gp120) inoculation significantly affected the
responses seen. Mice given SV(mIL-15) 3 d after
SV(gp120) did not make detectable gp120-specific cyto-
toxic responses. Simultaneous inoculation with SV(mIL-
15) and SV(gp120), however, increased specific cytolysis
to ≥ 20%, which was significant at E:T = 20:1 (P ≤ 0.05,
using Student's t-test) compared to SV(gp120) alone. The
most dramatic results were observed when SV(mIL-15)
was administered 3 d before SV(gp120). Those mice dem-
onstrated highly significant augmentation by SV(IL-15) of
gp120-specific lysis, which was ≥ 60% at both 20:1 and
10:1 E:T ratios (P ≤ 0.02 using Students' t-test, compared
with immunization of SV(gp120) alone). Mice injected
×2 with SV(mIL-15) alone made no significant gp120-
specific cytolytic responses at either 20:1 or 10:1 effec-
tor:target ratios. Mice given only SV(gp120) demonstrated
≈ 10% specific lysis at E:T = 20:1.
Effect of IL-15 co-administration on anti-gp120 antibody 
responses
Mice receiving SV(mIL-15) and/or SV(gp120) (or the con-
trol vector, SV(HBS)) according to the schedules outlined
above were tested to determine the effect, if any, of such
co-administration in anti-gp120 serum antibody
responses. CELISA and calculation of gp120-specific anti-
body binding were performed as described in Methods.
Slight binding antibody activity was detected 2 weeks after
the first inoculation(s), in all SV(gp120) recipient groups.
Levels of SV(gp120)-induced groups made detectable
antibody responses were not appreciably affected by coad-
ministration of SV(mIL-15) (data not shown).
Discussion
In this study, we used rSV40 vectors to elicit HIV-1NL4-3
gp120-specific cytotoxic lymphocyte and antibody
responses. We have observed that these vectors may be
administered repeatedly to boost those responses. Further
studies also suggested that such responses are durable in
vivo. Our results here demonstrate several important
strengths of using rSV40 vectors to immunize against len-
tiviral antigens: Among these are the ability of the vector
to be administered multiple times without eliciting neu-
tralizing responses [11-13], and the magnitude of the
cytotoxic responses to the vector-encoded lentiviral target
antigen. When SV(gp120) was given alone, i.e. without
added SV(mIL-15), levels of specific cytotoxicity increased
with additional SV(gp120) injections: After 2 injections, ≈
20% specific lysis was seen, which increased to >70% spe-
cific lysis after 7 injections. The potency of rSV40 immu-
nization to elicit cytotoxic immune responses is
underscored by the fact that these responses were meas-
ured in direct 51Cr-release assays: unselected lymphoid
organ populations were added directly to labeled target
cells at low E:T ratios, and specific 51Cr release was
measured.
Analysis to confirm CD8 expression, or expression of
other CTL markers was not performed on the effector
cells. However, it is unlikely that these data reflect the
cytotoxic activity of NK cells. NK cytolytic activity is non-
Western analysis of IL-15 expression in culture supernatants from SV(mIL-15)-transduc d P815 cellsFigure 3
Western analysis of IL-15 expression in culture supernatants 
from SV(mIL-15)-transduced P815 cells P815 cells were 
transduced with SV(mIL-15) at a m.o.i. = 100. 1.5, 3 and 6 
days post-transduction, culture supernatants were collected. 
Cultures were then stimulated with Con A and additional 
supernatants harvested 24 and 72 hours later. IL-15 secre-
tion into supernatants was visualized by Western analysis. 
Recombinant human IL-15 (rhIL-15) was the positive control 
(non-adjacent lane). Supernatants from unstimulated cultures 
were tested in parallel (non-adjacent lane).Page 7 of 11
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immunization. The patterns of 51Cr release observed in
the current studies were extensively controlled to ascertain
the antigen-specificity of the cytolysis observed: back-
ground lysis of wild type P815 cells was subtracted, as was
lysis by lymphocytes from mice immunized with an irrel-
evant rSV40 vector. We also found that cytolysis increased
with increasing numbers of immunizations, which is not
a characteristic of NK cell-mediated lysis.
Since a key goal for a vaccine against HIV is to generate
immune responses that are durable in vivo, we tested
whether cytotoxic lymphocyte activity elicited by
SV(gp120) immunization, was detectable one month
after inoculation. Thus, cytolytic responses, assayed one
month after a second injection, were ≈ 20%, which is
comparable to those of splenic cytotoxic cells assayed four
days following a third inoculation (data not shown). Fur-
ther, mice given multiple injections of SV(gp120), then
rested for one year, gave ≈ 70% specific lysis when chal-
lenged with SV(gp120). Therefore, SV(gp120) administra-
tion may thus favor development of cytotoxic lymphocyte
memory.
In an attempt to accelerate and to improve upon these
specific cytotoxic and particularly cytotoxic memory
responses, we co-immunized mice with SV(gp120) and a
rSV40 carrying mouse IL-15. IL-15 promotes cytotoxic
lymphocyte responses, and in particular, cytotoxic mem-
ory responses [23,24]. The biological effects of IL-15 are
less well understood than are those of some of the other
immunostimulatory cytokines that have been applied to
these types of immunization protocols, such as IL-2, IL-12
and IFN-γ. IL-15 is not a T cell-derived product, but rather
appears to be produced by a variety of cells, such as epi-
thelial cells, stromal cells and muscle. It acts on activated
T cells, sometimes similarly to IL-2, but it has activities
distinct from those of IL-2. IL-15 may play a role in T cell
activation in the CNS. It also promotes cytotoxic
responses, cytotoxic T cell memory, and natural killer
(NK) cell maturation [33,34].
Accordingly, our analysis of the contribution by IL-15 to
cytotoxic responses, focused mainly on the ability of
SV(mIL-15) to augment specific cytotoxic responses of
spleen cells from animals rested 1 month following
immunization. Because quiescent cytotoxic T cells are not
Specific cell-mediated responses against gp120-expressing target cells by splenic effectors from co-immunized miceFigure 4
Specific cell-mediated responses against gp120-expressing target cells by splenic effectors from co-immunized mice Mice were 
given two monthly injections with either SV(mIL-15), SV(gp120) or both cytokine and antigen sequentially or simultaneously IP. 
One month after the final inoculation(s), unselected spleen cells were assayed for specific cytolytic activity against gp120-
expressing clone 24 cells labeled with 51Cr, as described in Methods. Results shown here represent ≥ 3 independent determi-
nations per data set.
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splenocytes prior to assay with Con A. Non-specific activa-
tion was used to avoid specifically enriching effector cell
population for gp120-specific cells in vitro. Furthermore,
low effector:target ratios (20:1 and 10:1) were used in
these assays. Our immunization protocols tested both
simultaneous and staggered administration of rSV40s car-
rying HIV-1NL4-3 gp120 and murine IL-15.
IL-15 co-immunization dramatically accelerated cytotoxic
responses, depending on the immunization regimen
used: Animals given SV(mIL-15) alone made no gp120-
specific cytolytic responses. Mice receiving 2 treatments
with a mixture of SV(gp120) and SV(mIL-15) gave much
higher specific lysis, depending on the coadministration
regimen, as compared to those receiving SV(gp120) alone
(≈ 10% specific lysis). Thus, among mice given staggered
injections of SV(mIL-15) and SV(gp120), the order of
cytokine administration greatly affected the response: if
SV(gp120)was given first, no detectable gp120-specific
cytolysis was observed. However, if the cytokine was given
first, followed 3 days later by SV(gp120), ≥ 60% specific
lysis was seen at both 20:1 and 10:1 effector:target ratios.
Why the order of cytokine administration should affect
antigen-specific responses so dramatically is not yet clear.
Cytokine given after, or together with antigen, may have
insufficient time to augment cytotoxic responses. In addi-
tion, Western analysis of IL-15 production showed that IL-
15 secretion was not detectable in supernatants beyond
36 hours, but could be stimulated subsequently. Thus, a
specific, possibly brief, window for IL-15 expression and
secretion may need to be attained, in order for its effects
on gp120-specific responses to be detectable. We observed
very high levels of specific lysis by these unselected effec-
tor populations following just two tandem injections of
SV(mIL-15) followed by SV(gp120).
The strong anti-lentiviral cytolytic responses we report
were observed in a strain of mouse, BALB/cJ, that gener-
ally mounts relatively weak type 1 T cell responses. The
finding of >60% cytolysis with two administrations of
SV(gp120) + SV(mIL-15), suggests that a strategy similar
to that described herein may be helpful in individuals
who would generate relatively low cytolytic responses.
Serum antibody levels assayed by CELISA where
SV(gp120) was administered alone, multiple times, were
detectable after two immunizations, and continued to
increase up to week 4 following the third immunization.
These responses were not further enhanced by subsequent
boosting immunizations. While specific antibody
responses against gp120 were detected in all experimental
groups following SV(gp120) and SV(mIL-15) co-immuni-
zation, IL-15 co-administration did not augment anti-
gp120 antibody levels, compared to gp120 alone. This
was to be expected, since IL-15 reportedly acts primarily
on T cell and NK cell functions, rather than on humoral
immune responses.
Our data argue in favor of using IL-15 as an adjuvant for
antigen-specific immune responses, particularly cytotoxic
lymphocyte responses. We also demonstrate that a single
transgene, administered multiple times (>3), may be very
effective at eliciting both humoral and cell-mediated
responses. These results thus both corroborate and extend
our previous observations [13,14,32], and suggest that
combining rSV40s encoding antigens and immunostimu-
latory cytokines sequentially in multi-administration reg-
imens may provide high levels of long-lasting immunity
against the target antigen.
Conclusions
Recombinant SV40-derived gene-delivery vectors, being
transparent to the immune system, can be given multiple
times to prime and boost immune responses against the
delivered antigens. Anti-vector immunity does not over-
whelm responses against the target antigens. As well, these
vectors elicit very high levels of antibody, and especially
cell-meditated immunity. Finally, combining the delivery
Table 1
Abbreviation Meaning
CELISA cell-based ELISA
E:T effector cell:target cell ratio
gp120 major HIV envelope glycoprotein, 120 kDa
HBS hepatitis B surface antigen
IFNγ interferon-gamma
mIL-15 mouse interleukin-15
NIH-ARRRP National Institutes of Health, AIDS Research Reference Reagent Program
pNPP p-nitrophenyl phosphate
VCB41 strain of vaccinia virus carrying gp120 coding sequences
wt wild typePage 9 of 11
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Genetic Vaccines and Therapy 2004, 2:10 http://www.gvt-journal.com/content/2/1/10of rSV40s bearing antigens with those bearing cytokines
such as IL-15 can enhance levels of immunity, particularly
long-term immunity. Clearly, much work remains. How-
ever, this approach offers promise as a strategy to immu-
nize against pathogens for which classical approaches
have not been adequately effective.
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